<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238030</url>
  </required_header>
  <id_info>
    <org_study_id>R-04-298</org_study_id>
    <nct_id>NCT00238030</nct_id>
  </id_info>
  <brief_title>Thyroxine Replacement in Organ Donors</brief_title>
  <official_title>Efficacy and Pharmacokinetics of Oral Thyroid Replacement Therapy in Organ Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare oral versus intravenous administration of thyroid hormone: 1) for reversibility of
      hemodynamic instability in organ donors, and, 2) the pharmacokinetics of oral vs iv thyroid
      administration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disruption of the hypothalamic-pituitary axis following brain death may lead to hemodynamic
      instability, peripheral vasodilation, and diabetes insipidus in organ donors, requiring the
      use of high doses of inotropes. Inotropes may cause ischemic injury to organs and
      intramyocardial ATP stores, resulting in organs unsuitable for transplantation, as well as, a
      reduction in post-transplant organ function. Therefore, some clinicians advocate the use of
      triple hormonal therapy in potential organ donors.

      Since intravenous T3(the intracellular active form of thyroxine) is unavailable, oral or
      intravenous T4 must be used, requiring the conversion of T4 to T3at the cellular level. This
      conversion is impeded by glucocorticoids which also are administered to organ donors for
      their immunomodulating effects. Since oral T3 is readily available, our first question is
      whether oral versus intravenous administration of T4 is comparable. If so, our next study is
      to determine the efficacy of oral T3 versus oral T4. Our hypothesis is oral T3 is superior to
      oral T4.

      Our study therefore will determine whether or not the oral route is suitable for
      administration of thyroid replacement therapy. The study will compare the pharmacokinetics of
      oral versus intravenous T4 administration in organ donors, as well as, determine its ability
      to wean intropes in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time patients require inotropic support prior to organ procurement.</measure>
    <time_frame>every hour following administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profiles of oral vs iv T3,T4</measure>
    <time_frame>hourly from time of administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of organs donated</measure>
    <time_frame>total number of organs donated at time of procurement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thyroid function derangements at time of brain death</measure>
    <time_frame>thyroid function q 4hrs following declaration of brain death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Brain Death</condition>
  <arm_group>
    <arm_group_label>po thyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo is iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iv thyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo is po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-thryoxine</intervention_name>
    <description>2 mcg/kg iv or 2 mcg/kg po at time of enrollment</description>
    <arm_group_label>po thyroxine</arm_group_label>
    <other_name>L-thyroxine</other_name>
    <other_name>Eltroxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iv thryoxine</intervention_name>
    <description>thyroxine 2 mcg/kg iv</description>
    <arm_group_label>po thyroxine</arm_group_label>
    <arm_group_label>iv thyroxine</arm_group_label>
    <other_name>L-thyroxine</other_name>
    <other_name>Eltroxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Brain death criteria established

          2. Consent for organ donation received

        Exclusion Criteria:

        1. immediate (&lt; 4 Hrs) organ retrieval anticipated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Sharpe, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre-UC+</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre-UC</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Novitzky D, Cooper DK, Chaffin JS, Greer AE, DeBault LE, Zuhdi N. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation. 1990 Feb;49(2):311-6.</citation>
    <PMID>2305461</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>January 4, 2011</last_update_submitted>
  <last_update_submitted_qc>January 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Michael D Sharpe</name_title>
    <organization>London Health Sciences Centre - University Hospital</organization>
  </responsible_party>
  <keyword>organ donation</keyword>
  <keyword>thyroid replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

